Liu Hongliang, Zhang Yu, Li Li, Cao Jimin, Guo Yujia, Wu Yongyan, Gao Wei
Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi, PR China.
Shanxi Province Clinical Medical Research Center for Precision Medicine of Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi, PR China.
Mol Ther Oncolytics. 2021 Jan 20;20:240-264. doi: 10.1016/j.omto.2020.12.014. eCollection 2021 Mar 26.
Fascin actin-bundling protein 1 (FSCN1) is a highly conserved actin-bundling protein that cross links F-actin microfilaments into tight, parallel bundles. Elevated FSCN1 levels have been reported in many types of human cancers and have been correlated with aggressive clinical progression, poor prognosis, and survival outcomes. The overexpression of FSCN1 in cancer cells has been associated with tumor growth, migration, invasion, and metastasis. Currently, FSCN1 is recognized as a candidate biomarker for multiple cancer types and as a potential therapeutic target. The aim of this study was to provide a brief overview of the FSCN1 gene and protein structure and elucidate on its actin-bundling activity and physiological functions. The main focus was on the role of FSCN1 and its upregulatory mechanisms and significance in cancer cells. Up-to-date studies on FSCN1 as a novel biomarker and therapeutic target for human cancers are reviewed. It is shown that FSCN1 is an unusual biomarker and a potential therapeutic target for cancer.
成束蛋白肌动蛋白结合蛋白1（FSCN1）是一种高度保守的肌动蛋白成束蛋白，可将F-肌动蛋白微丝交联成紧密的平行束。据报道，多种人类癌症中FSCN1水平升高，且与侵袭性临床进展、预后不良和生存结果相关。FSCN1在癌细胞中的过表达与肿瘤生长、迁移、侵袭和转移有关。目前，FSCN1被认为是多种癌症类型的候选生物标志物和潜在治疗靶点。本研究的目的是简要概述FSCN1基因和蛋白质结构，并阐明其肌动蛋白成束活性和生理功能。主要重点是FSCN1在癌细胞中的作用及其上调机制和意义。综述了FSCN1作为人类癌症新型生物标志物和治疗靶点的最新研究。结果表明，FSCN1是一种不同寻常的生物标志物和癌症潜在治疗靶点。
Zotero 插件
